Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000392
Status:
COMPLETED
Last Update Posted:
2017-02-28
First Post:
2000-01-17
Brief Title:
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment
Sponsor:
National Institute of Mental Health NIMH
Organization:
National Institute of Mental Health NIMH
Study Overview
Official Title:
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals
Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients
Patients are randomized to receive either peptide T or placebo for the first 6 months All patients then receive open-label peptide T for approximately 6 additional months Neuropsychologic tests are used to determine drug effects
Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients
Patients are randomized to receive either peptide T or placebo for the first 6 months All patients then receive open-label peptide T for approximately 6 additional months Neuropsychologic tests are used to determine drug effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None